Post-market safety signals of energy-based surgical devices: a cross-specialty disproportionality analysis of the FDA MAUDE database with robotic-platform validation and regulatory triangulation, 2015–2025
Journal of Robotic Surgery · 12.10.2026 · 20 (1)
DOI: 10.1007/s11701-026-04060-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Robotic Surgery, online erschienen am 12.10.2026. Verfasst von Ruifeng Shi. Beteiligte Einrichtung: Xsail Surgical Co., Ltd, Shanghai, China. spark914@foxmail.com. Hauptthemen laut MEDLINE: Robotic Surgical Procedures, Product Surveillance, Postmarketing, Databases, Factual, Electrosurgery. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Post-market safety evidence for energy-based surgical devices is fragmented. We characterized adverse-event signals in the FDA MAUDE database, validated them on a third (robotic) platform, and triangulated across regulatory and international sources. Medical Device Reports (2015–2025) under electrosurgical and ultrasonic product codes were analyzed with reporting odds ratios (RORs), stratified by specialty and procedure, with robustness checks. All reports under the robotic-system code were retrieved as a third-platform validation cohort. Signals were triangulated with FDA recalls, 510(k) clearances, the Health Canada and Australian TGA databases, exposure descriptors, and a retrospectively applied Poisson CUSUM feasibility analysis. Among 110,183 deduplicated reports (65.8% electrosurgical, 34.2% ultrasonic), electrosurgical devices showed an electrical–thermal fingerprint (burns ROR 3.84; electric shock ROR 15.34) and ultrasonic devices a mechanical-integrity fingerprint (foreign-body removal ROR 92.74), replicated directionally in Canada and Australia. The fingerprint localized to generator/monopolar components and varied by specialty and procedure. Within the robotic validation cohort, component-stratified analysis partly reproduced these signatures—robot-mounted monopolar instruments retained a burn signal, and robot-mounted ultrasonic instruments carried the highest injury-report share—while cross-platform, same-modality contrasts are reported strictly as report-composition (share-level) comparisons. Reporting artifacts (19.5% placeholder narratives; a 2025 robotic mass-reporting episode comprising 55.8% of the robotic cohort) left fingerprint RORs materially unchanged. A retrospectively applied CUSUM flagged the burn theme more than five years before the 2023–2024 Class I recalls, illustrating—without establishing prospective lead time—the potential of automated monitoring. Energy-modality failure–injury fingerprints were consistent across specialties, delivery platforms, three national databases, and regulatory actions. Automated, artifact-aware surveillance of vigilance databases is a promising complement to pre-market review and warrants prospective evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Xsail Surgical Co., Ltd, Shanghai, China. spark914@foxmail.com.
Zitieren
APA
Shi, R. (2026). Post-market safety signals of energy-based surgical devices: a cross-specialty disproportionality analysis of the FDA MAUDE database with robotic-platform validation and regulatory triangulation, 2015–2025. Journal of Robotic Surgery, 20(1). https://doi.org/10.1007/s11701-026-04060-7
Vancouver
Shi R. Post-market safety signals of energy-based surgical devices: a cross-specialty disproportionality analysis of the FDA MAUDE database with robotic-platform validation and regulatory triangulation, 2015–2025. Journal of Robotic Surgery. 2026;20(1). doi:10.1007/s11701-026-04060-7
BibTeX
@article{Shi2026,
author = {Shi, Ruifeng},
title = {Post-market safety signals of energy-based surgical devices: a cross-specialty disproportionality analysis of the FDA MAUDE database with robotic-platform validation and regulatory triangulation, 2015–2025},
journal = {Journal of Robotic Surgery},
year = {2026},
volume = {20},
number = {1},
doi = {10.1007/s11701-026-04060-7}
}
EUVIMED